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Crystal Structure of an Inactive
Akt2 Kinase Domain
pressed in mammalian cells, evidence suggests that the
relative isoform expression levels differ between tissues.
Akt 1 appears to be the predominantly expressed iso-
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Amgen Cambridge Research Center form in most tissues, while Akt2 is highly enriched in
insulin target tissues [10]. Akt1-deficient mice appearOne Kendall Square
Building 1000 normal with respect to glucose tolerance and insulin-
stimulated glucose clearance from blood but displayCambridge, MA 02139
severe growth retardation [14, 15]. Cells derived from
Akt1-deficient mouse embryos are also more suscepti-
ble to proapoptotic stimuli. In contrast to what is ob-Summary
served in Akt1 null mice, disruption of the Akt2 locus by
homologous recombination results in insulin resistanceAkt/PKB represents a subfamily of three isoforms from
the AGC serine/threonine kinase family. Amplification and a diabetes mellitus-like phenotype [16]. These stud-
ies support the nonredundant function of Akt isoformsof Akt activity has been implicated in diseases that
involve inappropriate cell survival, including a number that likely relates to isoform-specific differences in ex-
pression levels, cofactor requirements, intrinsic sub-of human malignancies. The structure of an inactive
and unliganded Akt2 kinase domain reveals several strate preference, and/or subcellular localization.
The activation of Akt requires a sequence of tightlyfeatures that distinguish it from other kinases. Most
of the  helix C is disordered. The activation loop in regulated biochemical events involving the direct bind-
ing of PI3K lipid products and phosphorylation by poten-this structure adopts a conformation that appears to
sterically hinder the binding of both ATP and peptide tially more than one kinase activity. Activation of recep-
tor tyrosine kinases or G protein-coupled receptors orsubstrate. In addition, an intramolecular disulfide bond
is observed between two cysteines in the activation stimulation of cells by mechanical forces leads to phos-
phatidylinositol-3-kinase activation and the subsequentloop. Residues within the linker region between the
N- and C-terminal lobes also contribute to the inactive increase in membrane pools of 3-phosphorylated phos-
pholipids [17]. The PI3K lipid products phosphatidylino-conformation by partially occupying the ATP binding
site. sitol-3,4,5-triphosphate (PIP3) and phosphatidylinositol-
3,4-bisphosphate (PIP2) function as second messengers
by serving as high-affinity binding sites for the PH do-Introduction
main of Akt [18–20]. The presence of PIP2 and PIP3 re-
cruits Akt to the plasma membrane, where it becomesAkt is the cellular homolog of v-Akt, an oncogene of the
Akt-8 murine leukemia virus [1–3]. The catalytic domain activated by phosphorylation on two specific sites,
Thr309 in the activation loop and Ser474 in the regulatoryof Akt shows highest amino acid sequence identity with
protein kinase A (PKA) and protein kinase C (PKC) and tail [19, 21–23]. Phosphorylation at both residues is re-
quired for full activation of the Akt isoforms [24, 25].was originally termed RAC (related to A and C kinases)
protein kinase, or protein kinase B (PKB) [4, 5]. Akt be- Although it has been well established that phosphoryla-
tion of Akt at Thr309 is catalyzed by 3-phosphoinosi-longs to the so-called AGC superfamily of serine/threo-
nine kinases, which also includes SGK and the ribo- tide-depedent protein kinase-1 (PDK-1) [26, 27], the
mechanism of Akt Ser474 phosphorylation remains less-somal S6 protein kinase [6]. Akt has been implicated
as the central mediator of many biological responses clearly defined [28]. The phosphorylation of Ser474 can
be mediated by a number of different kinases and, possi-associated with the phosphatidylinositol 3-kinase (PI3K)
signal transduction pathway [7, 8]. For example, Akt bly, by an autophosphorylation mechanism [29]. Initially,
PDK-1 was shown to be converted to a kinase thatsignaling has been shown to stimulate glucose uptake,
glycogen and protein synthesis, and the promotion of phosphorylates S474 only upon association with a se-
quence that corresponds to the C terminus of proteincell survival in response to a variety of growth factors
[9, 10]. kinase C-related kinase-2 [30]. In addition to this PDK-1
complex, both the integrin-linked kinase [31] and p38-Mammals have three isoforms of this kinase, desig-
nated Akt1, Akt2, and Akt3. Akt2 and Akt3 show 81% dependent MK-2 [32] can also phosphorylate Akt at
Ser474 in various cell lines.and 83% amino acid sequence identity, respectively,
with Akt1 [3] (reviewed in [10, 11, 12]). The Akt isoforms Several lines of research suggest that abnormal levels
of Akt activation influences tumorigenesis. Mutationsshare a common domain organization that consists of
a pleckstrin homology domain (PH domain) at the N that compromise PTEN activity, a tumor suppressor
gene that functions to antagonize PI3K activation ofterminus, a kinase catalytic domain, and a short regula-
tory region at the C terminus [3, 11, 12] (reviewed in Akt, are found in a number of malignancies, including
glioblastoma, melanoma, and carcinomas of the pros-[13]). Although the Akt isoforms are ubiquititously ex-
tate, lung, endometrium, and head and neck [20, 33–36].
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Table 1. Data Collection and Refinement Statistics
Akt2 Akt2 Soaked in 20 mM DTT
Resolution (A˚) 2.8 2.8
Space group P41212 P41212
Unit cell (a, b, c) (A˚) 150.0, 150.0, 39.1 150.4, 150.4, 40.2
Mol/ASU 1 1
Rsym/Rhigh (%) 5.5/16.2 7.1/18.9
Reflections (total/unique) 63,147/11,332 50,158/11,257
Completeness (%) 98.3 94.4
Protein atoms 2,090 2,074
Water molecules 98 74
Rcryst/Rfree (%) 22.7/27.7 25.7/30.7
Rms deviations
Bond lengths (A˚) 0.0091 0.0091
Angles () 1.50 1.43
Overexpression of dominant-negative variants of Akt determined by molecular replacement, with the struc-
ture of PKA kinase domain in the ternary complex asenhances apoptosis and interferes with PI3K-induced
transformation in some cell lines [37]. Furthermore, the the search model [41]. The current structure has been
refined to an R factor of 22.7% (Rfree of 27.7%). Akt2direct amplification of wild-type Akt protein and activity
is also detected in several cell lines derived from breast residues omitted from the model because of disorder
include the N-terminal residues 143–145, residues 190–[38–40], ovarian [38], and prostate cancer [40]. These
findings suggest that elevated levels of Akt signaling 201 of  helix C, residues 298–310 of the activation loop,
and C-terminal residues 441–481. Data collection andinfluence tumorigensis by promoting cell survival through
the suppression of apoptosis. crystallographic refinement statistics are shown in Ta-
ble 1.Inhibiting Akt kinase activity is an attractive avenue
for therapeutic intervention in a variety of human malig- Similar to previously determined structures of both
protein serine/threonine and tyrosine kinases, Akt2-KDnancies. As an initial step toward inhibitor design, we
have determined the structure of the Akt2 kinase domain is bilobal, with a deep cleft between the two lobes.
(Figure 1A). The smaller N-terminal lobe is a twisted five-by X-ray crystallography. The structure provides insight
into a molecular mechanism of serine/threonine kinase stranded antiparallel  sheet with one partially ordered
 helix (C). The larger C-terminal lobe is mostly  heli-autoregulation that had not previously been described.
This information provides a basis for understanding the cal. The secondary structure nomenclature used in this
report follows that of PKA [41].structural constraints relieved upon Akt kinase activa-
tion and a possible explanation for the role of Ser474
phosphorylation in the activation process. Comparison of Akt2-KD and PKA
The kinase domain of Akt shares 43% amino acid se-
quence identity with that of PKA and 49% sequenceResults and Discussion
identity with that of PKC (Figure 2). Crystal structures
have been determined for the kinase domain of only oneStructure Determination and Overall Fold
Full-length human Akt2 with a six-histidine tag added other AGC family member, namely, PKA [41–47]. In all
previously reported crystal structures of PKA, the en-at the N terminus was expressed in the baculovirus/
insect cell system. The kinase domain, residues 143– zyme is phosphorylated and exhibits an active confor-
mation. The Akt2-KD structure is the first description of481, was obtained after digestion with Lys-C. The pure
Akt2-KD was found to be monophosphorylated at Thr an inactive AGC kinase domain. Together with PKA, the
Akt2-KD structure provides a unique comparison of AGC451 by LC-MS/MS. The Akt2-KD protein used in the
crystallization studies was determined to have insuffi- kinases in both active and inactive conformations.
One general feature of protein kinases is variationcient catalytic activity for enzymatic characterization.
However, the Akt2-KD is enzymatically competent after between the positions of the N- and C-terminal lobes,
resulting in different conformational states of the kinaseactivation with PDK1. In a standard radiometric filter
binding assay with crosstide (10 M), activated Akt2- domain. Crystallographic studies on active PKA reveal
three conformation states: open (apo structure and bi-KD (10 nM) has an apparent Km of 148 M for ATP
and a kcat/Km of 58 s1 M1. An IC50 value for stauro- nary complex with a peptide inhibitor, PKI) [47], interme-
diate (binary complex with adenosine or balanol) [45,sporine was determined to be 76 nM for activated
Akt2-KD. The current study focuses on structural stud- 46], and closed (ternary complex with PKI and Mn2-
AMPPNP or Mg2-ATP) [43, 47]. The relative orientationies of the inactive Akt2-KD.
Crystals diffracting to 2.8 A˚ were obtained and belong of the two lobes in apo Akt2-KD is most similar to that
of PKA in the closed conformation (Figure 1B). However,to the tetragonal space group P41212, with one molecule
per asymmetric unit. Western blot analysis of the Akt2 the N-terminal lobe of Akt2-KD is rotated about 6 rela-
tive to that in the closed form of PKA.crystals revealed that neither Thr309 nor Ser474 was
phosphorylated (data not shown). The structure was The N terminus of the PKA kinase domain begins
Molecular Mechanism for Autoinhibition of PKB/Akt
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Figure 1. Structure of the Kinase Domain of
Unphosphorylated Akt2
(A) Ribbon diagram showing the overall fold
of the Akt2 kinase domain.
(B) Backbone trace of Akt2 and PKA in which
the C atoms of the -helical cores are super-
posed. Akt2, blue; PKA, red. The Cs of PKA
in the closed conformation in the ternary
complex is used here. (A) was prepared with
MOLSCRIPT, and (B) was prepared with
GRASP.
with an amphipathic  helix that lies primarily along the  Helix C
A distinguishing feature of the Akt2-KD structure is thatC-terminal lobe [41]. On the basis of secondary structure
the first eight residues of  helix C in Akt2-KD are disor-predictions, Akt lacks an equivalent helix (Figure 2). In-
dered.  helix C plays a very important role in all proteinstead, Akt appears to have a flexible hinge that connects
kinases. Residue Glu91 in  helix C of PKA is hydrogenthe kinase domain to the N-terminal regulatory PH do-
bonded to the catalytic residue Lys72, which interactsmain. The truncated Akt2-KD crystallized in this study
with the  phosphate of ATP. Both residues are highlydoes not include a significant portion of the hinge se-
conserved in all protein kinases, and the correspondingquence. An obvious structural difference between the
residues are Glu200 and Lys181 in Akt2. Glu200 is disor-N-terminal lobes of PKA and Akt2-KD is seen in the 
dered in our structure, and the side chain of Lys181 ishelix C. Residues from the  helix C in PKA interact with
not correctly positioned for catalysis.both the activation loop and the C-terminal hydrophobic
The benzyl rings of Phe347 and Phe350 in the C-ter-motif. The majority of  helix C in Akt2-KD, however, is
minal FXXF hydrophobic motif of PKA are buried in twodisordered. The N-terminal lobes of Akt2-KD and PKA
hydrophobic pockets formed by residues of the N-ter-are similar, with a root-mean-square deviation (rmsd) of
minal lobe. These residues include residues Ile85 and1.0 A˚ for a superposition of all the C atoms, excluding
Leu89 from  helix C. The corresponding residues Val194the N-terminal helix in PKA and the disordered portion
and Val198 in Akt2-KD are disordered, and there is alsoof  helix C in Akt2-KD.
no electron density observed for the C-terminal FXXF
Comparison of the C-terminal lobes of PKA and Akt2-
motif.
KD shows good alignment of the -helical cores (rmsd
of 1.2 A˚). The region of greatest dissimilarity occurs in
ATP Binding Sitethe activation loop. The activation loop in PKA is solvent
The ATP binding pocket in the structure of Akt2-KDexposed and oriented away from the active site. In con-
reported here appears inaccessible. A superposition oftrast, the ordered segments of the activation loop of
C-terminal lobes of the apo Akt2-KD and the PKA ternaryAkt2-KD are inserted into the ATP and peptide binding
complex reveals that the side chains of Tyr231 and
sites. Residues C-terminal to the kinase domain in PKA
Phe294 of Akt2 occupy the pocket where the adenosine
extend over a large surface area of both the N-terminal
ring of ATP is bound (Figure 3B). The phenolic ring of
and C-terminal lobes [41]. In the structure of inactive Tyr231 and the benzyl ring of Phe294 lie side by side, at
Akt2-KD, the C-terminal chain extends over the C-ter- an angle of approximately 30, with strong hydrophobic
minal lobe and terminates near the ATP binding site, with interactions between the two side chains. Additionally,
the remaining 40 residues disordered. The last ordered Phe294 and Gly295 of Akt2-KD would intersect with the
residue in the structure of Akt2-KD is Asp440. The C phosphates of ATP. Tyr231 is part of a short strand that
of Asp440 in Akt2 is 6.3 A˚ away from its homologous links the two lobes in Akt2-KD, and the corresponding
residue, Asp329, in PKA. The structural divergence in linker region in protein kinases plays a crucial role in the
the C-terminal tail seems to start at Phe426 of Akt2. binding of the adenosine base through both hydrogen
Superposition of the C-terminal segment of Akt2 (be- bonding and hydrophobic interactions. Phe294 and
tween Phe426 and Asp440) and its counterpart in PKA Gly295 of Akt2 are part of the Asp-Phe-Gly (DFG) motif
shows an rmsd of 2.7 A˚. The C terminus of PKA ends conserved in the activation loop of all protein kinases.
with a sequence of FTEF, while the C-terminal FPQF The aspartic acid of the DFG sequence in PKA is in-
motif in Akt2 is followed by a crucial, second phosphory- volved in the coordination of the two Mg2 ions associ-
lation serine, 474, and seven more residues. On the ated with ATP.
basis of sequence comparison, the region between the In the ternary complex of PKA, the planar adenosine
conserved Phe-Asp (439-440 in Akt2) and the FXXF motif ring of ATP is involved in numerous hydrophobic interac-
tions with residues Leu49, Val57, Ala70, Val104, Met120,would be different between Akt and PKA.
Structure
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Figure 2. Domain Structure of Akt2 and PKA and Sequence Alignment of the Kinase Domain of the AGC Family
(A) Schematic representation of full-length Akt2 and PKA. The potential phosphorylation sites of Akt2 and PKA are labeled. Note that PKA
terminates at the C-terminal of the conserved FXXF motif and lacks a regulatory phopshorylation site equivalent to S473 of Akt.
(B) Structure-based sequence alignment of the kinase domains of Akt1, Akt2, Akt3, and other AGC family members, including PKA, PKC,
Sgk, and S6K. The secondary structure elements are shown above the sequence. Residues that block the ATP binding, cyan highlight; residues
that block the peptide substrate binding, yellow highlight; phosphorylation site at Thr309, purple highlight; last visible residue in the structure
of Akt2, red highlight; FXXF motif, gray highlight.
Molecular Mechanism for Autoinhibition of PKB/Akt
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Figure 3. The ATP Binding Site of Akt2
(A) The ATP binding site of Akt2, showing the
hydrophobic interactions of residues Tyr231
and Phe294 with residues Leu158, Val166,
Ala179, Thr213, Met229, Ala232, Met282, and
Phe439.
(B) Superposition of Akt2 and ATP of the PKA/
ATP/PKI ternary complex. The superposition
is based on the C’s of the C-terminal lobes
in Akt2 and PKA. Note that, in the binding site
of Akt2, the adenosine ring of ATP (red) is
occupied by residues Tyr231 and Phe294
(yellow), while the binding of ATP phosphates
is blocked by residues Phe294 and Gly295.
(C) Electron density map of Akt2 around the
ATP binding site. The 2Fo  Fc electron den-
sity map is contoured at 1 .
Glu121, Tyr122, Val123, Leu173, Thr183, and Phe327. KD appears blocked. In the PKA ternary complex, the
inhibitory PKI peptide adopts an extended conformationThese residues are conserved in Akt2; they are Leu158,
Val166, Ala179, Thr213, Met229, Glu230, Tyr231, Ala232, and interacts with PKA around the phosphate acceptor
residue (P site). Residues Leu296, Cys297, Cys311, andMet282, Thr292, and Phe439, respectively. However, in
the inactive Akt2-KD structure, some of these conserved Thr313 from the activation loop of Akt2-KD intersect
with PKI near the P-1, P-2, and P-3 sites (Figure 4). Theresidues adopt very different conformations. For exam-
ple, Tyr231 and Phe294 occupy the binding pocket for peptide substrate consensus sequences for both Akt
and PKA indicate a bulky hydrophobic residue in thethe adenosine ring of ATP. The specific conformation
of Tyr231 and Phe294 are further stabilized by several P1 position. Residues Leu198, Pro202, and Leu205 in
PKA form a hydrophobic groove that surrounds the sidesurrounding residues, including Phe439, which is posi-
tioned about 6 A˚ away from Phe327, the equivalent resi- chain of isoleucine in PKI at P1. Although these resi-
dues are conserved as Phe310, Pro314, and Leu317 indue in PKA (Figure 3A).
Akt2, a similar hydrophobic groove does not exist in the
inactive apo Akt2-KD structure. Residue Leu317 in Akt2-Peptide Substrate Binding Site
A superposition of the PKA ternary complex with the KD remains in almost the same position as Leu205 in
PKA. However, residue Pro314 is positioned more thanapo Akt2-KD structure was used to compare the peptide
substrate binding pockets in these two activation states. 8 A˚ from the P1 site, while the charged side chain of
Glu315 lays in the equivalent position to proline in theThe binding pocket for peptide substrate in the Akt2-
Figure 4. The Substrate Peptide Binding Site
of Akt2
(A) Superposition of Atk2 and the substrate
peptide PKI of the PKA/ATP/PKI ternary com-
plex. The superposition is based on the C’s
of the C-terminal lobes in Akt2 and PKA. PKI,
red; disulfide bond formed between Cys297
and Cys311, yellow.
(B) Superposition of the binding site of pep-
tide substrate of Akt2 and ternary PKA. Akt2
is represented in molecular surface, and PKI
of ternary PKA is represented in rods. Note
that the P1 hydrophobic pocket (in PKA) is
occupied by a charged residue, Glu315, in
Akt2, whose surface is colored in red. Also
note that residues Leu296, Cys297, Cys311,
and Thr313 (surfaces colored in purple, yel-
low, cyan, and green, respectively) block the
binding of P-1, P-2, and P-3 sites.
Structure
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Figure 5. The Activation Loop of Akt2
Molecular surface representation of inactive Akt2, IRK, and ERK2, with the activation loops shown in tubes. The kinases are shown in similar
orientations to those in Figure 1.
ternary complex. Residue Phe310 is disordered in the first reported mechanism of autoinhibition is observed in
kinases, such as FGF [59], c-Src [60, 61], and ERK2Akt2-KD structure, but would appear to be too distal
from the P1 site on the basis of the distance of the [62, 63], in which the activation loop blocks peptide
substrate binding while the ATP binding site remainsnearest ordered residues from this site. Judging from
these observations, the inactive Akt2-KD would need to accessible. A second mechanism of autoinhibition is
observed upon comparison of the active and inactiveundergo a substantial conformational change in order
to form a P1 hydrophobic pocket similar to that ob- IRK structures [64, 65]. In this mechanism, the binding
sites for both substrate peptide and ATP are blockedserved in the PKA ternary complex.
by residues from the activation loop. The structure of
the inactive apo Akt2-KD indicates a mechanism of au-Activation Loop Disulfide
In the activation loop of Akt2-KD, Cys297 forms a disul- toinhibition similar to, and more complex than, that of
IRK. Residues from the linker region and the activationfide bond with Cys311. Cys297 follows the DFG motif
at the N terminus of the activation loop, while Cys311 loop of Akt2 occupy the ATP binding site, while addi-
tional activation loop residues block the peptide sub-is located near the C-terminal end of the activation loop.
These two cysteines are conserved in other AGC family strate binding site. The residues in the activation loop
of Akt-KD are relatively well structured, with an averagemembers. Previous studies have demonstrated that the
cysteine residues equivalent to Cys311 in PKA, cGMP- B factor of 47.3 A˚2. AMP-PNP/Mg2 at 4 mM and stauro-
sporine at 1 mM did not bind to the protein in the crystalsdependent protein kinase (PKG), and PKC are reactive
and can be covalently modified [48–57]. Furthermore, (data not shown). Attempts to cocrystallize these same
ligands with the inactive Akt2-KD were unsuccessful.phosphorylase kinase (PhKg) has two cysteines, Cys172
and Cys184, corresponding to Cys297 and Cys311 of Binding studies are needed to determine the affinities
of ATP and peptide substrate to the inactive Akt2-KDAkt2, and these cysteines are also involved in intramo-
lecular disulfide bonds, albeit with two additional cys- in solution. On the basis of primary sequence align-
ments, this mechanism of autoinhibition may be broadlyteines located distal to the activation loop [58]. The
physiological relevance of these two disulfides is not applicable to other AGC family kinases (Figure 2). In the
context of full-length AGC kinases, the structural roleclear.
The observed disulfide bond in the activation loop of of additional regulatory domains (such as the PH domain
in Akt) in kinase autoinhibition remains to be investi-Akt2-KD is sensitive to reducing agent, as it is broken
in the structure solved with a crystal soaked in cryo gated.
Full activation of Akt requires phosphorylation at bothbuffer containing 20 mM DTT. This results in an even
larger portion of the activation loop becoming disor- Thr309 in the activation loop and Ser474 in the C-ter-
minal regulatory domain. The role of phosphorylation ofdered, including residues Leu296, Cys297, Cys311,
Gly312, and Thr313. However, residues Pro314 and critical serines/threonines or tyrosines in the activation
loop to activate protein kinases is well understood. TheGlu315 still adopt the same unusual conformation seen
in the disulfide-containing structure. As a result, the phosphorylated activation loops adopt open conforma-
tions, stabilized by ionic interactions between phos-activation loop of reduced, crystalline Akt2-KD does not
appear to interfere with the P-1, P-2, and P-3 sites but phorylated side chains and basic residues, as revealed
in the structures of ternary complexes of active PKAstill blocks the P1 site hydrophobic pocket. Addition-
ally, the ATP binding site appears inaccessible in this and IRK [43, 47, 65]. Activation is usually accompanied
by lobe closure and an additional rotation of  helix Cstructure.
toward the C-terminal lobe that places a glutamic acid
residue (Glu200 in Akt2) in proximity to a lysine residueMechanism for Autoinhibition and Activation
Previous crystallographic studies of protein kinases (Lys181 in Akt2), both of which are highly conserved in
protein kinases. Thr309 is not phosphorylated and ishave defined two general autoinhibition mechanisms,
which are mediated by the activation loop (Figure 5). The disordered in the Akt2-KD structure. The corresponding
Molecular Mechanism for Autoinhibition of PKB/Akt
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residue, Thr197, in PKA is phosphorylated, with the the stabilization of the activated state by non-activation
loop-phosphorylated side chains.phosphate interacting with side chains of Arg165 and
Lys189. Arg274 in the Akt2-KD structure is in the same Cys297 and Cys311 in the activation loop of Akt form
a disulfide bond in the unphosphorylated Akt2-KD struc-position as Arg165 in PKA, while Lys298 is disordered. If
Thr309 is phosphorylated and ligated similarly to active ture and are redox sensitive. Among known kinases,
these cysteines are conserved in most members of thePKA, Thr309 would need to move by more than 16 A˚.
A large conformational change of the activation loop, AGC kinase family (such as Akt, PKC, S6K, and SGK),
one member of the CAMKK family (PhKg), and two mem-which would largely unblock the ATP and peptide sub-
strate binding pockets, would be required. bers of the OPK family (HRI and YKL516) [66]. The physi-
ological significance of the observed disulfide bond inThe role of Ser474 phosphorylation in full activation
of Akt is less well understood. Ser474 is located imme- the reducing environment is not clear. However, studies
have shown that PKC activity is sensitive to glutathiola-diately C-terminal to a conserved hydrophobic motif,
designated the “FXXF” motif in the AGC kinase family tion, a reversible oxidative modification, suggesting that
the redox status of the cell plays a role in regulating AGC(Figure 2). Mutagenesis studies with PKA have demon-
strated that the FXXF region is important for catalytic kinases (reviewed in [67]). Despite numerous reports of
oxidative regulation of PKC, PKA, and Akt, the preciseactivity [41]. The side chains of the two phenylalanines
in the FXXF segment of PKA are accommodated by two molecular mechanism(s) for this type of redox regulation
is not well understood. Disulfide formation in the activa-adjacent hydrophobic pockets located in the N-terminal
lobe. Although the same hydrophobic pockets appear tion loop provides a plausible mechanism for the oxida-
tive inactivation of these kinases. However, additionalto exist in Akt2-KD (despite the disorder of some side
chains in the hydrophobic pockets), the FXXF region is studies are needed to further investigate the biological
implication of the disulfide bond.disordered and not observed in the structure. On the
basis of homology modeling with PKA, Ser474 can be Inhibiting Akt is an attractive approach for therapeutic
intervention into a variety of human malignancies. Theplaced in the vicinity of several polar residues of  helix
C in Akt2-KD. In this location, phosphorylated Ser474 present studies suggest that designing inhibitors into
the ATP binding site of inactive Akt may pose a signifi-could potentially interact with Arg202 and Gln205 of 
helix C. These interactions may help lock the FXXF motif cant challenge. Binding of inhibitors in the ATP binding
cleft will require significant rearrangement of regionsin the hydrophobic pockets and place  helix C in an
active conformation. PKA terminates with the FXXF mo- surrounding the ATP binding site. Predictions of such
rearrangements are difficult to make from the currenttif, and the equivalent C-terminal phosphorylation site
to Ser474 does not exist. PKA, however, has a unique unligated structure. However, designing inhibitors against
the inactive conformation of Akt might be achieved byN-terminal amphipathic helix, which makes extensive
contacts with the kinase core. This helix is critical to interfering with the proposed mechanism of phospho-
Ser474-mediated activation. On the basis of the structurethe relative orientation of the N-terminal and C-terminal
lobes as well as the optimal positioning of  helix C of Akt2-KD and homology modeling with PKA, inhibitors
that prevent proximal association of phosphorylatedand the FXXF motif in active PKA. Secondary structure
predications reveal no such helix N-terminal to the ki- Ser474 with Arg202 and Gln205 may be effective by
preventing the optimal positioning of  helix C. Targetingnase core in Akt. This may explain the necessity of a
C-terminal phosphorylation site for Akt in stabilization inhibitors to the FXXF binding site may effectively block
phosphorylated Ser474-mediated activation of Akt. Theof the activated conformation of Akt, similar to that of
the N-terminal helix for PKA. Since the C-terminal phos- composition of the FXXF binding site among AGC kinase
family members appears to be more divergent than thephorylation residue is highly conserved in other mem-
bers of AGC family that do not contain an N-terminal ATP binding site. As a result, targeting the FXXF binding
site in Akt may provide an avenue for developing potentamphipathic helix, the proposed activation mechanism
for Akt could also be used by these kinases. and selective inhibitors of this enzyme.
Experimental ProceduresBiological Implications
Protein Expression and Purification
Akt signaling has been demonstrated to influence the Akt2 was cloned by PCR with a human first strand cDNA from fetal
liver (Clontech) as the template. Primers 5-GGTCGGATCCATGAATprogression of tumorigenesis, in part, by promoting cell
GAGGTGTCTGTCATCAAA-3 and 5-CAGAGAATTCACTCGCGGAsurvival. Akt activation is tightly coupled to multiple lev-
TGCTGGCCGAGTA-3 were used to give a full-length cDNA encod-els of regulation involving a balance between PTEN
ing human Akt2. The resulting PCR product was cloned into thephosphatase and PI3K activities, membrane transloca-
BamHI and EcoRI sites of a derivative of pFastBac1 (Life Technolo-
tion, and trans-phosphorylation by multiple kinases. Full gies) containing a sequence coding for His6 followed by a thrombin
Akt activation is known to require phosphorylation at site. The resulting vector was used to produce a recombinant bacu-
lovirus. Two rounds of amplification in Sf9 insect cells gave theboth Thr309 in the activation loop and Ser474 in the
high-titer virus used in generating cell paste. Cell paste containingC-terminal tail. The present structure of an unliganded
His6Akt2 was lysed and processed for immobilized metal affinityAkt2-KD provides the first structural analysis of an inac-
chromatography, essentially as described by the manufacturer (Thetive AGC family kinase and offers several novel modes
QIAexpressionist; Qiagen). The pool of affinity-enriched His6Akt2 (52of Ser/Thr kinase autoinhibition, including steric hin- mg; 2.5 mg/ml) was diluted to 0.5 mg/ml with 25 mM Tris (pH 8.5),
drance of ATP and peptide substrate binding by amino 10% glycerol, 2.5 mM NaCl, and 5 mM ME and digested overnight
at 4C with 13.5 nM LysC. The digestion was quenched with 0.5 mMacids from the linker region and the activation loop and
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leupeptin, and analysis by SDS-PAGE revealed the major protease- Joseph Kim, Dr. David Armistead, and Dr. Nick Lydon for helpful
comments throughout the project.resistant product to be a doublet at 42 kDa. Purification of the
major species in the doublet was achieved by anion exchange chro-
matography and then by gel exclusion chromatography with Super- Received: May 30, 2002
dex-75 resin (Pharmacia Biotech). The final Akt2 protein appeared Revised: September 24, 2002
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Accession Numbers
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tein Data Bank under accession codes 1MRY and 1MRV.
Note Added in Proof
While this paper was being reviewed, Yang et al. [68] published three
structures of an inactive Akt2 kinase domain. Their observations are
similar to ours, except that Yang et al. do not observe the disulfide
bond in the activation loop.
